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Abstract
Understanding the mechanisms regulating tissue specific and stimulus inducible regulation
is at the heart of understanding human biology and how this translates to wellbeing, the
ageing process, and disease progression. Polymorphic DNA variation is superimposed as
an extra layer of complexity in such processes which underpin our individuality and are the
focus of personalized medicine. This review focuses on the role and action of repetitive
DNA, specifically variable number tandem repeats and SINE-VNTR-Alu domains, highlight-
ing their role in modification of gene structure and gene expression in addition to their
polymorphic nature being a genetic modifier of disease risk and progression. Although
the literature focuses on their role in disease, it illustrates their potential to be major con-
tributors to normal physiological function. To date, these elements have been under-
reported in genomic analysis due to the difficulties in their characterization with short
read DNA sequencing methods. However, recent advances in long read sequencing meth-
ods should resolve these problems allowing for a greater understanding of their contribution
to a host of genomic and functional mechanisms underlying physiology and disease.
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Introduction
Ninety-eight percent of the human genome does not code
for proteins, but contains a variety of regulatory elements
including those to direct (a) tissue specific and stimulus
inducible gene expression, (b) differential mRNA splicing
to generate distinct protein profiles or turnover, and (c)
functional non-coding RNAs. The properties of these reg-
ulatory components like the exons themselves can be mod-
ified by genetic polymorphism or mutations. To date,
genome analyses have favored short read next generation
DNA sequencing and genome-wide association studies
(GWAS). The latter has focused on analyzing variation in
single nucleotide polymorphisms (SNPs) and has identi-
fied genomic variation in strong association with pheno-
type both in exons and non-coding regions. Such SNPs in
exons are often easy to interpret mechanistically as many
will change a key amino acid providing an explanation for
the phenotypic association. However, the functional signif-
icance of the vast majority of SNPs in non-coding DNA is
difficult to determine; furthermore, a major shortfall of this
approach is that it has neglected the role and function of
other sources of genetic variation in the genome such as
that represented by repetitive DNA. This is in part due to
the inherent instability of human repetitive DNA in E. coli
cloning strategies used in the construction of the library of
DNA sequences incorporated into the reference genome,
and the difficulties in interpreting and reassembling
sequence from such short read sequences in areas of repet-
itive DNA. The advent of long-read sequencing technologies
will help overcome the latter problem, and technologies such
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as Oxford Nanopore or Pacific Biosciences single-molecule
real-time sequencing (PacBio) can easily read 10kb or more
sequence; furthermore, base calling accuracy has improved
(error rate said to be <1% for PacBio and <5% for Oxford
Nanopore) and analytical pipelines to call structural varia-
tion have been developed.1 This review will focus on one
class of repetitive DNA, namely variable number tandem
repeats (VNTRs), highlighting their functional roles in
genome regulation and as biomarkers of disease focusing
on neurological diseases and disorders
Consequences and genetic nature of tandem
repeat DNA
Tandem repeat (TR) DNA imparts a huge source of varia-
tion to the genome, and TRs have evolved throughout evo-
lution and contribute to genetic diversity. Although they
are found in many eukaryote species, present day interest
has focused on their role in hominid evolution and their
contribution to the development of human-specific traits in
the evolution of modern humans and in particular neural
function.2–4 In modern humans, TR DNA has been associ-
ated both with traits such as aggression and addictive
behaviors, reviewed by literature5–8 and implicated in the
increased susceptibility to, and risk of developing, a
wide variety of neurological diseases such as motor
neuron disease9–11 and Alzheimer’s disease 12,13 mental
health conditions such as bipolar disorder, depression,
and schizophrenia.14,15 To date, 1584 such repeats have
been found to be human specific and it has been proposed
that they contribute to human-specific traits.4 When the
repeat number is variable, i.e. polymorphic, they become
VNTRs, a class which accounts for approximately 3% of the
human genome16,17; such repeat elements can vary in copy
number and additionally demonstrate single nucleotide
variation within the repeats or even short insertions or dele-
tions. There are several mechanisms proposed, by which
this variation could develop, including errors in DNA rep-
lication such as slipped-strand mispairing which results in
the misalignment of DNA strands and thus expansion or
contraction of the copy number of the DNA motifs,18
homologous recombination, and duplications. Recently it
has been shown 55% of VNTRs map to the terminal
5Mbp of human chromosomes,19,20 and regions that have
previously been found to demonstrate increased double-
strand breaks during early stages of meiosis21,22 and male
meiotic recombination. VNTRs may be located within
exons, introns, or intergenic spaces and this aforemen-
tioned group of VNTRs appears to favor intronic locations.4
A second pathway contributing to the derivation of VNTRs
is via retrotransposition, particularly utilizing the compos-
ite SINE-VNTR-Alu (SVA) element, and these elements
tend to show bias against incorporation in to genic regions,
and have a high GC content.4 Unsurprisingly, VNTRs locat-
ed within exons are the smallest group. Originally the main
focus of research was on short tandem repeats (STR) (or
micro-satellites) as it became apparent that expansions of
these can occur in somatic cells, and this phenomenon is
implicated in diseases such as fragile X-associated tremor/
ataxia syndrome, myotonic dystrophy, Huntington’s
disease, spinocerebellar ataxia, and amyotrophic lateral
sclerosis (ALS).23–33 This approach originally identified a
number of diseases associated with triplet expansions, i.e.
Fragile X syndrome in 1991 23 and Huntington’s disease in
1993;34 however, expansions of longer repeat sequences
have since been found. For the latter, examples include:
pentanucleotide expansions in the genes SAMD12 and
RFC1 found in benign adult familial myoclonal epilepsy
type1 and ataxia syndromes, respectively,35,36 a hexanu-
cleotide repeat expansion in the C9ORF72 gene associated
with ALS,32,33 and a 12-nucleotide expansion in the CSTB
gene associated with progressive myoclonic epilepsy of the
Unverricht-Lundberg type or EPM1 37 (Table 1). To date,
incidences of personal somatic expansions or generation-
to-generation instability in TRs of much larger repeat
length have not been identified other than the intriguing
recent report of an expanded VNTR sequence (around 25
nucleotides in length) in an intron of the ABCA7 gene, and
the repeat number ranges from 12 to 427 or greater, and has
been identified as a risk factor in Alzheimer’s disease; how-
ever, it has not been reported whether the repeat number
seen in this expansion is stable between germ and somatic
cells from the same individual.13 In general, based on cur-
rent sequence information, the polymorphic but stable
expansions seen in longer TRs appear to pre-date the evo-
lution of modern human populations and have been used
to track ancient population migrations. Furthermore, for
some VNTRs, the allele frequencies or base pair composi-
tion of the repeat unit have been found to differ between
populations and ethnic groups throughout the world
including TRIB3,47 WRD7,42 and DNAJC5/miR-941.48 This
is a factor which must be taken into account when assign-
ing “risk” to such alleles as exemplified by the hexanucleo-
tide expansion associated with ALS in the C9ORF72 gene
which is one of the four most common causes of ALS in
Caucasian populations but is much rarer in Chinese and
other East Asian populations.39,49
Assessing the functional potential of
VNTRs as transcriptional regulators of
gene expression
An increasing number of VNTRs have been identified
which support differential gene expression both in vivo
and in vitro. Perhaps one of the earliest and most striking
illustrations of allele-specific activity, was the in vivo dem-
onstration of the ability of the human-specific SLC6A4
intron 2 VNTR to direct differential reporter gene expres-
sion in the midbrain of mouse embryos equivalent to the
area where the mouse serotonin transporter is initially
expressed in the developing brain.43,50 Association studies
have established a link between repeat copy number in this
VNTR as a risk factor in various neurological diseases or
disorders; however, establishing the functional significance
of such VNTR polymorphism in situ is more problematic.
Some of this difficulty may be attributed to non-coding
VNTRs being regulatory domains that are only functional
in specific tissues, developmental stages, or in response to
specific cellular challenges. Recent examples of VNTRs
found to have regulatory properties include the finding
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that the longer risk alleles of the intronic VNTR in ABCA7
favored use of a cryptic splice site resulting in exon skip-
ping 12 and that the number of VNTR repeats in the pro-
moter region of TRIB3 correlated with mRNA levels in
various tissues.47
If VNTRs are involved in transcriptional or post tran-
scriptional gene regulation then they will act in consort
with other gene regulatory domains to direct tissue specific
and stimulus inducible gene expression. For example, it has
been shown that a VNTR located at theMIR137 locus works
together with the SNP rs2660304 to drive differential pro-
moter activity in vitro, thereafter it was shown using hap-
lotype analysis at the MIR137 locus that rs2660304 was a
proxy SNP for the schizophrenia GWAS SNP rs1625579.51
Furthermore, interactions between multiple VNTRs to reg-
ulate gene expression are possible. In vitro analysis has
demonstrated that distinct VNTRs within a gene locus
can act either independently or synergistically to regulate
transcription. For example, the serotonin transporter
(SLC6A4) gene which has VNTRs located both in the
linked polymorphic region of the 50 promoter and intron
2 which have been shown to act combinatorically,52 a fur-
ther example is the MAOA gene which in addition to the
well-characterized mVNTR has a second distal (d)VNTR44
located approximately 500 bp upstream of the mVNTR.53
The complexity this produces was illustrated by the
recent meta-analysis of MAOA by Tunbridge et al. where
it was found that the high and low activity m alleles were
associated with enzyme activity in the blood but did not
affect MAOA mRNA abundance;45 concurrently, Manca
et al. demonstrated that the distal VNTR regulated mRNA
levels of the canonical isoform of MAOA in a cell line
model.54 Moreover, specific regulatory effects on MAOA
isoforms and an additive effect of the two VNTRs at this
locus were highlighted in additional work.53 A further
layer of intricacy was uncovered by the finding that
VNTR (allele) specific responses to a stimulus also
existed.54 Thus, it is important to consider the overall hap-
lotype when analyzing gene regulation rather than assum-
ing a single regulatory variation is solely associated with a
specific phenotype.47,53
Proposed mechanisms of action and
emerging novel roles for VNTRs to alter
the genomic transcriptome
In addition to the more conventional mechanism of provi-
sion of transcription factor (TF) binding domains by which
VNTRs can contribute to the regulation of transcription,
there are several examples of them encoding miRNAs
and affecting epigenetic parameters (Figure 1). In general,
VNTRs have been shown to function as transcriptional reg-
ulatory domains, by providing binding sites for transcrip-
tion factors and modulating the affinity of binding on the
basis of repeat unit copy number.55–57 More specifically in
the context of neurological disorders, the previously men-
tioned SLC6A4 intron 2 VNTR has been assessed via report-
er gene assays in rat prefrontal cortical cells, where it was
found that the different copy number variants induced
reduced but differential reporter gene expression in
Table 1. Examples from the text of neurological diseases and disorders which have been associated with polymorphic tandem repeats.
Gene STR/VNTR/SVA Disease association Refs
FMR1 STR (triplet) Fragile X-associated tremor/ataxia syndrome 23,24
DMPK STR (triplet) Myotonic dystrophy type 1 28,29
HTT STR (triplet) Huntington’s disease 30,34
ATXN1 STR (triplet) Spinocerebellar ataxia type 1 11,31
amyotrophic lateral sclerosis
NIPA1 STR (triplet) Hereditary spastic paraplegia type 6, amyotrophic lateral sclerosis 9
NOTCH2NLC STR (triplet) Neuronal intranuclear inclusion disease-related disorders, Parkinson’s disease 38
SAMD12 VNTR
(pentamer)
















Attention-deficit hyperactivity disorder 40,41
DRD4 VNTR
(48 mer)
Attention deficit hyperactivity disorder, addictive, and eating disorders 5,8
WRD7 VNTR
(69 mer)
Amyotrophic lateral sclerosis 42
SLC6A4 VNTR




(30 mer and decamer)
Impulsive/anti-social/aggressive behaviors, affective disorders 6,44,45
TAF1 SVA X-linked dystonia Parkinsonism 46
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response to CCCTC-binding factor (CTCF).52 Furthermore,
it has been shown that both SLC6A4 VNTRs can bind mul-
tiple transcription factors, including y-box binding protein
(YB1), CTCF and methyl-CpG binding protein (MeCP2),
inducing allele-specific expression profiles in response to
cocaine.58 A further example is the VNTR identified in the
30 UTR of the human dopamine transporter (SLC6A3) gene,
which has been associated with attention-deficit hyperac-
tivity disorder.40,41 Previously it had been shown using
reporter gene assays in the SH-SY5Y cell line that the
SLC6A3 VNTR induced significant repression of luciferase
expression in response to the HESR (HEY) family of tran-
scription factors, specifically HESR1 and HESR2.59
More recently, it has been discovered that some VNTRs
have the potential to encode for miRNAs. This phenome-
non has been recently described for VNTRs within the
genes WDR7 42 and DNAJC5 which harbors the human-
specific miR-941 within an intronic VNTR.48 This latter
example displays unusual features for a recently emerged
human-specific miRNA, namely high levels of expression,
particularly of note with regard to this review, in the cere-
bellum and prefrontal cortex and the copy number demon-
strates a high level of variability. Human-specific
regulation by this miRNA has been shown in the brain,
targets included the host gene DNAJC5 whose protein has
amongst other functions a role in neurotransmitter
release,48 preventing neurodegeneration 60 and is associat-
ed with adult-onset neuronal ceroid lipofuscinosis.61
Furthermore, this poses the question does the copy
number of the VNTR leads to distinct levels of the
miRNA directly, or is the mechanism indirect, achieved
by modification of the processing of the internal miRNA?
The putative miRNA encoded within WDR7 (incidentally
itself a target of miR-94148) has been detected in cytoplas-
mic aggregates or speckles when experimentally over-
expressed. Such RNA foci, albeit in these cases nuclear,
are recognized as important features in a number of RNA
gain of function disease models such as that for myotonic
dystrophy 62 and C9ORF72-associated ALS.63,64
Epigenetic modification of a VNTR could have signifi-
cant consequences for all VNTR-directed regulatory mech-
anisms in both the immediate response to cellular
signalling and the medium- and long-term properties of
the VNTR to modulate gene function. This was illustrated
by the analysis undertaken by Vasiliou et al. regarding the
response of the SLC6A4 serotonin transporter gene to stim-
ulation by cocaine—differential effects on transcription
factor binding were seen dependant on which VNTR
allele was being examined and correlated with MeCP2
binding.58 One clear mechanism is methylation of the
VNTR itself, this requires the VNTR to contain CpG targets.
Simplistically, the more CpG in the VNTR, the greater
opportunity for methylation changes to alter VNTR func-
tion. This is perhaps obvious in short repeats of CG, but can
also occur in expansion repeats such as the hexamer
CCCCGG tandem repeat found in C9ORF72.65,66 Changes
in the status of CpG methylation have long been noted to
affect the stability of repetitive elements containing such
sequences; furthermore, methylation status has been pur-
ported to enable DNA to adopt alternative non-B DNA
structural forms such as Z-DNA.67 Consideration of the
methylation status of the VNTR may help explain some
of the conflicting reports of the association of repetitive
elements with traits and disease. A prime example of this
is theMAOA gene reviewed by Ziegler and Domschke, and
this highlighted that the mVNTR lies in an area that exhibits
Figure 1. Mechanisms by which tandem repeat DNA can modify gene expression. Differential regulation at an allele can result either as a result of polymorphic repeat
number, SNPs or indels in the repeats, pathogenic expansion of the repeat or in the case of SVAs presence or absence polymorphism. (A color version of this figure is
available in the online journal.)
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differential methylation; furthermore, the level of methyla-
tion is postulated to contribute to the different disease pro-
files that have been attributed to the MAOA gene, and the
location of MAOA on the X chromosome could also con-
tribute to the gender differences seen in the various analy-
ses.68 This observation was expanded by Manca et al., who
demonstrated in a cell line model that there was allele-
specific gene expression and transcription factor binding
with corresponding allele-specific epigenetic marks in the
region encompassing the mVNTR; furthermore, exposure to
the mood stabilizer sodium valproate resulted in an allele-
specific response in transcription factor binding and epige-
netic marks.54
The final mechanism to be highlighted is modification of
genome structure and in particular formation of G-quad-
ruplexes (G4). These structures can be generated by repeti-
tion of C-rich hexameric sequences such as CCCTCC and
CCCCGG and variants thereof. The classical model for G4
structure is the trimeric repeat of CCCTCCCC found in the
MYC gene promoter which has been associated with pro-
moter usage for MYC expression.69,70 Although this exam-
ple is not a VNTR, it has laid the basis for the putative
action of such repeats found in VNTRs in mechanisms
involved in disease progression or initiation as exemplified
by the CCCCGG expansion repeat in the C9ORF72 gene
associated with ALS.71 Such repeats are postulated to
form a genomic structure that allows for torsional strain
on one side and opening of the genome on the other thus
allowing for a range of distinct structural parameters to be
imposed at local regions of the genome. A number of tran-
scription factors, both double stranded DNA binding fac-
tors such as CTCF and Sp1, and single stranded nucleic
acid binding factors, such as hnRNPK and YB1, could
then bind to such VNTRs to determine localized genomic
structure.
VNTRs in non-long terminal repeat
retrotransposons
VNTRs are often considered as standalone elements in the
genome but as discussed earlier they are also key domains
of larger functional components such as the compound
SINE-VNTR-Alu (SVA) element, a non-long terminal
repeat retrotransposon. Although the total number of
SVAs in the human reference genome is modest (approx.
2700), SVAs are hominid-specific elements with almost 50%
of those characterized in the reference genome found to be
human specific and have been postulated to correlate with
the development of hominid lineage-specific traits.2 They
are composite regulatory DNA domains containing
multiple regulatory components (Figure 2) that affect
reporter gene expression.72 Several of these domains are
tandem repeats, specifically the CT hexamer flanking
domain and a central large VNTR domain. The VNTR com-
ponent of the SVA is variable in length, and it can consist of
a single VNTR or two separate VNTRs (which are not nec-
essarily both variable in number) which may share related
primary sequence but are clearly distinct from one another.
The VNTR may also contain more than one specific repeat
motif. SVAs also have the potential to form the structural
components outlined above, namely G-quadruplexes, and
this ability is embedded in the CT hexamer and the central
VNTR region where the CpG content can approach 60%.
The association of SVAs with disease may not only be a
modifying parameter but can also be causative of the dis-
ease. This supports the main drive of our hypothesis that
VNTRs are not only biomarkers of disease but can also be
mechanistically involved in progression of the disease. This
is demonstrated by the observation that some SVAs can be
polymorphic for their presence or absence in the genome,
thus for specific SVAs this means that they can be (1) asso-
ciated with methylation differences at adjacent promoters
as exemplified by the LRIG2 gene,73 (2) associated with
differential RNA expression and disease severity in
Parkinson’s disease (Pfaff et al. in preparation), and (3) caus-
ative of disease as seen in X chromosome-linked dystonia
Parkinsonism.46
Summary
This review highlights the emerging field analyzing the role
and importance of VNTRs in regulation of genome function
and regulation of the cell transcriptome. These elements
have the potential to function in many different ways and
have been postulated to contribute to human evolution. It is
apparent, however, that each individual element should
not be considered alone, rather it is their concerted action
that is important, and this provides a layer of intricacy to
regulation allowing an exquisite and specific response to a
stimulus. In the recent past, VNTRs have also been found to
be linked with many neurological conditions and disorders
and their activity is expected to explain some of the missing
heritability in such disorders. To date, analysis of VNTRs in
association studies has often relied on labor intensive tech-
niques such as polymerase chain reaction (PCR), which
itself can be technically challenging in these domains due
to their repetitive nature and in some instances, high GC
content. However, with the advent and increased availabil-
ity of long-read sequencing methods, these problems will






Figure 2. Illustration of the consensus structure of the non-long terminal repeat retrotransposon SVA element (0.7–4 kb). The VNTR and CT elements can both be
polymorphic for the number of tandem repeats and individual single repeat elements can also be polymorphic with SNPs and/or indels, and the polyA (An) may also be
polymorphic in length. The element is flanked by target site duplications (TSD).
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analysis thus aiding the identification of a host of genomic
and functional mechanisms underlying our physiology. For
example, long-read sequencing has recently enabled the
identification of a short tandem repeat (GGC) expansion
in the NOTCH2NLC locus which can have as many as 517
repeats in affected individuals with neuronal intranuclear
inclusion disease-related disorders38 and facilitated epige-
nomic profiling of transposable elements.74
AUTHORS’ CONTRIBUTIONS
JNGM, JPQ, and VJB conceived the idea, all authors reviewed
the literature, wrote, and edited the article.
DECLARATION OF CONFLICTING INTERESTS
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of this
article
FUNDING
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship, and/or publication of this
article: JNGMwas funded by a Medical Research Council doc-
toral training studentship [grant number MR/N013840/1].
AIL was funded by a Wellcome Trust PhD Studentship
[grant number 109095/Z/15/Z]. ALP and SK are funded by
MSWA, The Michael J. Fox Foundation, Shake It Up Australia
and The Perron Institute. JPQ and VJB are funded by the
Andrzej Wlodarski Memorial Research Fund.
ORCID iDs
Abigail L Pfaff https://orcid.org/0000-0002-2231-9800
Sulev Koks https://orcid.org/0000-0001-6087-6643
Vivien J Bubb https://orcid.org/0000-0003-2763-7004
REFERENCES
1. Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME, Gouil Q.
Opportunities and challenges in long-read sequencing data analysis.
Genome Biol 2020;21:30
2. Vasieva O, Cetiner S, Savage A, Schumann GG, Bubb VJ, Quinn JP.
Potential impact of primate-specific SVA retrotransposons during the
evolution of human cognitive function. Trends Evol Biol 2017;6:DOI:
10.4081/eb.2017.6514
3. Kim K, Bang S, Yoo D, Kim H, Suzuki S. De novo emergence and
potential function of human-specific tandem repeats in brain-related
loci. Hum Genet 2019;138:661–72
4. Sulovari A, Li R, Audano PA, Porubsky D, Vollger MR, Logsdon GA,
Human Genome Structural Variation C, Warren WC, Pollen AA,
Chaisson MJP, Eichler EE. Human-specific tandem repeat expansion
and differential gene expression during primate evolution. Proc Natl
Acad Sci U S A 2019;116:23243–53
5. McGeary J. The DRD4 exon 3 VNTR polymorphism and addiction-
related phenotypes: a review. Pharmacol Biochem Behav 2009;93:222–9
6. Kolla NJ, Vinette SA. Monoamine oxidase a in antisocial personality
disorder and borderline personality disorder. Curr Behav Neurosci Rep
2017;4:41–8
7. Xiang C, Liu S, Fan Y, Wang X, Jia Y, Li L, Cong S, Han F. Single nucle-
otide polymorphisms, variable number tandem repeats and allele
influence on serotonergic enzyme modulators for aggressive and sui-
cidal behaviors: a review. Pharmacol Biochem Behav 2019;180:74–82
8. Botticelli L, Micioni Di Bonaventura E, Del Bello F, Giorgioni G,
Piergentili A, Romano A, Quaglia W, Cifani C, Micioni Di
Bonaventura MV. Underlying susceptibility to eating disorders and
drug abuse: genetic and pharmacological aspects of dopamine D4
receptors. Nutrients 2020;12:2288
9. Blauw HM, van Rheenen W, Koppers M, Van Damme P, Waibel S,
Lemmens R, van Vught PWJ, Meyer T, Schulte C, Gasser T, Cuppen
E, Pasterkamp RJ, Robberecht W, Ludolph AC. Veldink JH, van den
berg LH. NIPA1 polyalanine repeat expansions are associated with
amyotrophic lateral sclerosis. Hum Mol Genet 2012;21:2497–502
10. Iacoangeli A, Al Khleifat A, Jones AR, Sproviero W, Shatunov A, Opie-
Martin S, Alzheimer’s Disease Neuroimaging I, Morrison KE, Shaw PJ,
Shaw CE, Fogh I, Dobson RJ, Newhouse SJ, Al-Chalabi A. C9orf72
intermediate expansions of 24-30 repeats are associated with ALS.
Acta Neuropathol Commun 2019;7:115
11. Tazelaar GHP, Boeynaems S, De Decker M, van Vugt JJFA, Kool L,
Goedee HS, McLaughlin RL, Sproviero W, Iacoangeli A, Moisse M,
Jacquemyn M, Daelemans D, Dekker AM, van der Spek RA,
Westeneng H-J, Kenna KP, Assialioui A, Da Silva N, Povedano M,
Pardina JSM, Hardiman O, Salachas F, Millecamps S, Vourc’h P,
Corcia P, Couratier P, Morrison KE, Shaw PJ, Shaw CE, Pasterkamp
RJ, Landers JE, Van Den Bosch L, Robberecht W, Al-Chalabi A, van
den Berg LH, Van Damme P, Veldink JH, van Es MA, Project Min
EALSSC. ATXN1 repeat expansions confer risk for amyotrophic lateral
sclerosis and contribute to TDP-43 mislocalization. Brain Commun
2020;2:fcaa064
12. De Roeck A, Duchateau L, Van Dongen J, Cacace R, Bjerke M, Van den
Bossche T, Cras P, Vandenberghe R, De Deyn PP, Engelborghs S, Van
Broeckhoven C, Sleegers K, Consortium B. An intronic VNTR affects
splicing of ABCA7 and increases risk of Alzheimer’s disease. Acta
Neuropathol 2018;135:827–37
13. De Roeck A, Van Broeckhoven C, Sleegers K. The role of ABCA7 in
Alzheimer’s disease: evidence from genomics, transcriptomics and
methylomics. Acta Neuropathol 2019;138:201–20
14. Lam D, Ancelin M-L, Ritchie K, Freak-Poli R, Saffery R, Ryan J.
Genotype-dependent associations between serotonin transporter gene
(SLC6A4) DNA methylation and late-life depression. BMC Psychiatry
2018;18:1–10
15. Pacheco A, Berger R, Freedman R, Law AJ. AVNTR regulates miR-137
expression through novel alternative splicing and contributes to risk
for schizophrenia. Sci Rep 2019;9:11793
16. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J,
Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K,
Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P,
McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J,
Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-
Thomann Y, Stojanovic N, Subramanian A, Wyman D, Rogers J,
Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N,
Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R,
French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A,
Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S,
Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S,
Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA,
Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe
SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB,
Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T,
Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett
N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M,
Gibbs RA, Muzny DM, Scherer SE, Bouck JB, Sodergren EJ, Worley
KC, Rives CM, Gorrell JH, Metzker ML, Naylor SL, Kucherlapati RS,
Nelson DL, Weinstock GM, Sakaki Y, Fujiyama A, Hattori M, Yada T,
Toyoda A, Itoh T, Kawagoe C, Watanabe H, Totoki Y, Taylor T,
Weissenbach J, Heilig R, Saurin W, Artiguenave F, Brottier P, Bruls T,
Pelletier E, Robert C, Wincker P, Smith DR, Doucette-Stamm L,
Rubenfield M, Weinstock K, Lee HM, Dubois J, Rosenthal A, Platzer
Marshall et al. Tandem repeats 1373
...............................................................................................................................................................
M, Nyakatura G, Taudien S, Rump A, Yang H, Yu J, Wang J, Huang G,
Gu J, Hood L, Rowen L, Madan A, Qin S, Davis RW, Federspiel NA,
Abola AP, Proctor MJ, Myers RM, Schmutz J, Dickson M, Grimwood J,
Cox DR, Olson MV, Kaul R, Raymond C, Shimizu N, Kawasaki K,
Minoshima S, Evans GA, Athanasiou M, Schultz R, Roe BA, Chen F,
Pan H, Ramser J, Lehrach H, Reinhardt R, McCombie WR, de la Bastide
M, Dedhia N, Bl€ocker H, Hornischer K, Nordsiek G, Agarwala R,
Aravind L, Bailey JA, Bateman A, Batzoglou S, Birney E, Bork P,
Brown DG, Burge CB, Cerutti L, Chen HC, Church D, Clamp M,
Copley RR, Doerks T, Eddy SR, Eichler EE, Furey TS, Galagan J,
Gilbert JG, Harmon C, Hayashizaki Y, Haussler D, Hermjakob H,
Hokamp K, Jang W, Johnson LS, Jones TA, Kasif S, Kaspryzk A,
Kennedy S, Kent WJ, Kitts P, Koonin EV, Korf I, Kulp D, Lancet D,
Lowe TM, McLysaght A, Mikkelsen T, Moran JV, Mulder N, Pollara
VJ, Ponting CP, Schuler G, Schultz J, Slater G, Smit AF, Stupka E,
Szustakowki J, Thierry-Mieg D, Thierry-Mieg J, Wagner L, Wallis J,
Wheeler R, Williams A, Wolf YI, Wolfe KH, Yang SP, Yeh RF, Collins
F, Guyer MS, Peterson J, Felsenfeld A, Wetterstrand KA, Patrinos A,
Morgan MJ, de Jong P, Catanese JJ, Osoegawa K, Shizuya H, Choi S,
Chen YJ, Szustakowki J. Initial sequencing and analysis of the human
genome. Nature 2001;409:860–921
17. Bakhtiari M, Shleizer-Burko S, Gymrek M, Bansal V, Bafna V. Targeted
genotyping of variable number tandem repeats with adVNTR. Genome
Res 2018;28:1709–19
18. Castillo-Lizardo M, Henneke G, Viguera E. Replication slippage of the
thermophilic DNA polymerases B and D from the euryarchaeota pyro-
coccus abyssi. Front Microbiol 2014;5:403
19. Audano PA, Sulovari A, Graves-Lindsay TA, Cantsilieris S, Sorensen
M, Welch AE, Dougherty ML, Nelson BJ, Shah A, Dutcher SK, Warren
WC, Magrini V, McGrath SD, Li YI, Wilson RK, Eichler EE.
Characterizing the major structural variant alleles of the human
genome. Cell 2019;176:663–75.e19
20. Linthorst J, Meert W, Hestand MS, Korlach J, Vermeesch JR, Reinders
MJT, Holstege H. Extreme enrichment of VNTR-associated polymor-
phicity in human subtelomeres: genes with most VNTRs are predom-
inantly expressed in the brain. Transl Psychiatry 2020;10:369
21. Nachman MW. Variation in recombination rate across the genome: evi-
dence and implications. Curr Opin Genet Dev 2002;12:657–63
22. Pratto F, Brick K, Khil P, Smagulova F, Petukhova GV, Camerini-Otero
RD. DNA recombination. Recombination initiation maps of individual
human genomes. Science 2014;346:1256442–42
23. Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DPA, Pizzuti A,
Reiner O, Richards S, Victoria MF, Zhang F, Eussen BE, van Ommen
G-JB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galjaard H,
Thomas Caskey C, Nelson DL, Oostra BA, Warren ST. Identification
of a gene (FMR-1) containing a CGG repeat coincident with a break-
point cluster region exhibiting length variation in fragile X syndrome.
Cell 1991;65:905–14
24. Kremer E, Pritchard M, Lynch M, Yu S, Holman K, Baker E, Warren S,
Schlessinger D, Sutherland G, Richards R. Mapping of DNA instability
at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science
1991;252:1711
25. Harley HG, Brook JD, Rundle SA, Crow S, Reardon W, Buckler AJ,
Harper PS, Housman DE, Shaw DJ. Expansion of an unstable DNA
region and phenotypic variation in myotonic dystrophy. Nature
1992;355:545–46
26. Buxton J, Shelbourne P, Davies J, Jones C, Tongeren TV, Aslanidis C,
Jong Pd Jansen G, Anvret M, Riley B, Williamson R, Johnson K.
Detection of an unstable fragment of DNA specific to individuals
with myotonic dystrophy. Nature 1992;355:547–48
27. Aslanidis C, Jansen G, Amemiya C, Shutler G, Mahadevan M, Tsilfidis
C, Chen C, Alleman J, Wormskamp NGM, Vooijs M, Buxton J, Johnson
K, Smeets HJM, Lennon GG, Carrano AV, Korneluk RG, Wieringa B,
Jong PJd. Cloning of the essential myotonic dystrophy region andmap-
ping of the putative defect. Nature 1992;355:548–51
28. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen
G, Neville C, Narang M, Barcelo J, O’Hoy K, Leblond S, Earle-
MacDonald J, de Jong PJ, Wieringa B, Korneluk RG. Myotonic dystro-
phy mutation: an unstable CTG repeat in the 3’ untranslated region of
the gene. Science 1992;255:1253–5
29. Fu YH, Pizzuti A, Fenwick RG, Jr., King J, Rajnarayan S, Dunne PW,
Dubel J, Nasser GA, Ashizawa T, de Jong P, Wieringa B, Korneluk R,
Perryman MB, Epstein HF, Caskey CT. An unstable triplet repeat in a
gene related to myotonic muscular dystrophy. Science 1992;255:1256–8.
30. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi
L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B,
Anderson MA, Wexler NS, Gusella JF, Bates GP, Baxendale S,
Hummerich H, Kirby S, North M, Youngman S, Mott R, Zehetner G,
Sedlacek Z, Poustka A, Frischauf A-M, Lehrach H, Buckler AJ, Church
D, Doucette-Stamm L, O’Donovan MC, Riba-Ramirez L, Shah M,
Stanton VP, Strobel SA, Draths KM, Wales JL, Dervan P, Housman
DE, Altherr M, Shiang R, Thompson L, Fielder T, Wasmuth JJ, Tagle
D, Valdes J, Elmer L, Allard M, Castilla L, Swaroop M, Blanchard K,
Collins FS, Snell R, Holloway T, Gillespie K, Datson N, Shaw D, Harper
PS. A novel gene containing a trinucleotide repeat that is expanded and
unstable on Huntington’s disease chromosomes. Cell 1993;72:971–83
31. Orr HT, Chung MY, Banfi S, Kwiatkowski TJ, Jr., Servadio A, Beaudet
AL, McCall AE, Duvick LA, Ranum LP, Zoghbi HY. Expansion of an
unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat
Genet 1993;4:221–6
32. DeJesus-HernandezM, Mackenzie Ian R, Boeve Bradley F, Boxer Adam
L, Baker M, Rutherford Nicola J, Nicholson Alexandra M, Finch NiCole
A, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung G-YR,
Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH,
Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL,
Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R.
Expanded GGGGCC hexanucleotide repeat in noncoding region of
C9ORF72 causes chromosome 9p-Linked FTD and ALS. Neuron
2011;72:245–56
33. Renton AE, Majounie E, Waite A, Simon-Sánchez J, Rollinson S, Gibbs
JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L,
Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz
SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO,
Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray
A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K,
Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A,
Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L,
Isoviita VM, Kaivorinne AL, H€oltt€a-Vuori M, Ikonen E, Sulkava R,
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